Gliclazide
Clazicon is a medicine that reduces blood sugar levels (an oral antidiabetic medicine, belonging to the sulfonylurea group). Clazicon is used in adults with a certain type of diabetes (type 2 diabetes), in whom diet, exercise, and weight loss alone are not enough to control blood sugar levels.
Before starting to take Clazicon, discuss it with your doctor or pharmacist. You should follow the treatment plan prescribed by your doctor to maintain proper blood sugar levels. This means, in addition to regular medication, following a diet, exercising, and, if necessary, losing weight. During treatment with gliclazide, you should regularly check your blood sugar levels (and, if necessary, your urine sugar levels) and, if necessary, your glycosylated hemoglobin (HbA1c) levels. For the first few weeks of treatment, the risk of significantly lowering blood sugar levels (hypoglycemia) may be increased. Therefore, close medical supervision is necessary. Low blood sugar levels (hypoglycemia) may occur:
In case of concomitant use of Clazicon with antibiotics belonging to the group of fluoroquinolones, especially in elderly patients, disturbances in blood glucose levels (low and high blood sugar levels) may occur. In this case, your doctor will remind you how important it is to monitor your blood glucose levels. If you or your family members have or have had a deficiency of glucose-6-phosphate dehydrogenase (G6PD) in the past (a disorder affecting red blood cells), a decrease in hemoglobin levels and red blood cell breakdown (hemolytic anemia) may occur. Before taking gliclazide, you should consult your doctor. In patients with porphyria (a genetic disease characterized by the accumulation of porphyrins or their precursors in the body), cases of exacerbation of porphyria have been reported after taking certain other sulfonylurea derivatives.
Gliclazide is not recommended for use in children due to the lack of data.
Tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, as well as any medicines you plan to take. The use of the following medicines may enhance the effect of gliclazide, leading to a decrease in blood sugar levels and the occurrence of symptoms of low blood sugar levels:
Clazicon may enhance the effect of concomitantly used anticoagulant medicines (e.g., warfarin). Before taking any other medicine, consult your doctor. In case of hospitalization, inform the medical staff about taking Clazicon.
Clazicon can be taken with food and non-alcoholic beverages. Consuming alcohol during treatment with gliclazide is not recommended, as it may unpredictably affect diabetes control.
Clazicon is not recommended during pregnancy. If you are pregnant, think you may be pregnant, or plan to have a baby, consult your doctor before taking this medicine. You should not take Clazicon while breastfeeding.
If your blood glucose levels are too low (hypoglycemia) or too high (hyperglycemia), or if you experience vision disturbances as a result of abnormal blood sugar levels, your ability to concentrate or react may be impaired. Remember that this can be dangerous for you or others (e.g., when driving a car or operating machines). Ask your doctor if you can drive, if:
If you have been told that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist. The dose of Clazicon is determined by your doctor based on your blood sugar levels. Changes in external factors (e.g., weight loss, lifestyle changes, stress) or improvement in blood sugar control may require a change in the dose of gliclazide. Dose of 30 mg: the recommended dose is one to four tablets (maximum 120 mg) once a day, at breakfast time. The number of tablets depends on your response to treatment. Dose of 60 mg: the tablet can be divided into equal doses. The recommended dose is half to two tablets (maximum 120 mg) once a day, at breakfast time. The number of tablets depends on your response to treatment. Oral administration. Take the tablet(s) with a glass of water during breakfast (preferably at the same time every day). Clazicon 30 mg tablets: swallow the tablet whole. Clazicon 60 mg tablets: swallow the tablet or half of it whole. Do not chew or crush the tablets. After taking the tablet(s), you should always eat a meal. If you are taking concomitant treatment with Clazicon and metformin, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists, or insulin, your doctor will determine the appropriate dose of each medicine individually for you. If you notice that your blood sugar levels are high despite taking Clazicon as prescribed, consult your doctor or pharmacist.
If you have taken too many tablets, contact your doctor or go to the emergency department of the nearest hospital immediately. The symptoms of overdose are the symptoms of low blood sugar levels (hypoglycemia) as described in section 2. "Important information before taking Clazicon". If you do not receive proper treatment, these symptoms may worsen and lead to drowsiness, loss of consciousness, and even coma. If you experience symptoms of hypoglycemia, you should immediately consume sugar (4-6 large sugar crystals) or a sweet drink, and then eat a snack or a meal. If you are unconscious, contact your doctor and call for emergency help immediately. The same applies if you accidentally take the medicine, e.g., a child. Do not give unconscious patients drinks or food. Inform another person about your illness, who, in case of need, can call for medical help.
It is important to take the medicine every day, as regular treatment has a better effect. However, if you miss a dose of Clazicon, take the next dose at the usual time. Do not take a double dose to make up for the missed tablet.
Since diabetes treatment usually lasts for the rest of your life, consult your doctor before stopping treatment with Clazicon. Stopping the medicine may lead to an increase in blood sugar levels (hyperglycemia), which increases the risk of developing diabetes complications. If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Clazicon can cause side effects, although not everybody gets them. Low blood sugar levels (hypoglycemia) are the most common side effect. Symptoms are described in section 2. "Important information before taking Clazicon".If you do not receive proper treatment, these symptoms may worsen and lead to drowsiness, loss of consciousness, and even coma.If your symptoms of hypoglycemia worsen or persist even after consuming sugar, you should immediately consult your doctor. Blood disorders There have been reports of a decrease in the number of certain blood cells (e.g., platelets, red and white blood cells). This may cause: pale skin, prolonged bleeding time, bruising, sore throat, fever. These symptoms usually disappear after stopping treatment. Liver disorders There have been reports of single cases of liver disorders causing yellowing of the skin and eyes. You should immediately consult your doctor if you experience these symptoms. These changes usually disappear after stopping the medicine. Your doctor will decide whether to stop treatment. Skin disorders There have been reports of the following skin disorders: rash, redness, itching, hives, blisters, angioedema (sudden swelling of the eyelids, face, lips, mouth, tongue, or throat, which can cause difficulty breathing). The rash may worsen and become widespread, or blisters may appear, or the skin may peel. If you experience these symptoms, you should stop taking Clazicon and immediately consult your doctor. Rarely, symptoms of severe hypersensitivity reactions (DRESS, Drug Rash with Eosinophilia and Systemic Symptoms) have been reported: initially in the form of flu-like symptoms and a rash on the face, which then spread and were accompanied by a high temperature. Gastrointestinal disorders Discomfort or abdominal pain, nausea, vomiting, indigestion, diarrhea, constipation. The occurrence of these symptoms can be alleviated by taking Clazicon as recommended, with a meal – see section 3. "How to take Clazicon".Eye disorders Short-term vision disturbances may occur, especially at the beginning of treatment. This is due to changes in blood glucose levels. As with other sulfonylureas, the following events have been reported: significant changes in blood cell counts and allergic vasculitis, decreased sodium levels in the blood (hyponatremia), symptoms of liver damage (e.g., jaundice), which in most cases disappeared after stopping treatment with sulfonylureas but may lead to life-threatening liver failure in individual cases.
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. There are no special precautions for storage. Do not use this medicine after the expiry date stated on the carton and blister after: EXP. The expiry date refers to the last day of the month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Clazicon 30 mg modified-release tablets are white, oval, biconvex, 5 x 11 mm in size, marked with the letter "G" on one side. Clazicon 60 mg modified-release tablets are white, oval, biconvex, 7 x 15 mm in size, with a score line on both sides, marked with the letter "G" on one side of the score line and the number "60" on the other side of the score line. The tablet can be divided into equal doses. Pack sizesClazicon 30 mg: blisters of 60 modified-release tablets. Clazicon 60 mg: blisters of 30, 60 modified-release tablets.
Synoptis Pharma Sp. z o.o. ul. Krakowiaków 65 02-255 Warsaw
Balkanpharma-Dupnitsa AD 3 Samokovsko Shosse Str. 2600 Dupnitsa Bulgaria
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.